Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
February 29, 2024 07:55 ET
|
Vericel Corporation
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% ...
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
February 27, 2024 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
February 15, 2024 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
February 05, 2024 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
January 09, 2024 07:55 ET
|
Vericel Corporation
Full-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million MACI Full-Year Revenue Expected to be...
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
January 03, 2024 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
November 08, 2023 07:55 ET
|
Vericel Corporation
Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year MACI Revenue Growth of 21% to $37.6 Million Full-Year 2023 Revenue Guidance Raised to $192.5-197.5...
Vericel to Present at the Stephens Annual Investment Conference
November 07, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
October 25, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
September 28, 2023 08:30 ET
|
Vericel Corporation
Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared...